Literature DB >> 20889352

An ATIPical family of angiotensin II AT2 receptor-interacting proteins.

Sylvie Rodrigues-Ferreira1, Clara Nahmias.   

Abstract

AT2, the second subtype of angiotensin II receptors, is a major component of the renin-angiotensin system involved in cardiovascular and neuronal functions. AT2 belongs to the superfamily of G protein-coupled receptors, but its intracellular signaling pathways have long remained elusive. Over the past few years, efforts to characterize this atypical receptor have led to the identification of novel molecular scaffolds that directly bind to its intracellular tail. The present review focuses on a family of AT2 receptor-interacting proteins (ATIPs) involved in neuronal differentiation, vascular remodeling and tumor suppression. Recent findings that ATIPs and ATIP-related proteins associate with microtubules suggest that they might constitute a novel family of multifunctional proteins regulating a wide range of physiopathological functions.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889352     DOI: 10.1016/j.tem.2010.08.009

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  19 in total

Review 1.  Angiotensin receptor-associated proteins: local modulators of the renin-angiotensin system.

Authors:  Hayo Castrop
Journal:  Pflugers Arch       Date:  2012-05-16       Impact factor: 3.657

Review 2.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

Review 3.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

4.  Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.

Authors:  Sylvie Rodrigues-Ferreira; Anne Nehlig; Hadia Moindjie; Clarisse Monchecourt; Cynthia Seiler; Elisabetta Marangoni; Sophie Chateau-Joubert; Marie-Eglantine Dujaric; Nicolas Servant; Bernard Asselain; Patricia de Cremoux; Magali Lacroix-Triki; Monica Arnedos; Jean-Yves Pierga; Fabrice André; Clara Nahmias
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-04       Impact factor: 11.205

Review 5.  Regulation of end-binding protein EB1 in the control of microtubule dynamics.

Authors:  Anne Nehlig; Angie Molina; Sylvie Rodrigues-Ferreira; Stéphane Honoré; Clara Nahmias
Journal:  Cell Mol Life Sci       Date:  2017-02-15       Impact factor: 9.261

6.  RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.

Authors:  Rukhsana Gul; Maya Ramdas; Chirag H Mandavia; James R Sowers; Lakshmi Pulakat
Journal:  Cardiorenal Med       Date:  2012-10-27       Impact factor: 2.041

Review 7.  Impact of the AT(2) receptor agonist C21 on blood pressure and beyond.

Authors:  Sébastien Foulquier; U Muscha Steckelings; Thomas Unger
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

Review 8.  Microtubule-Associated Protein ATIP3, an Emerging Target for Personalized Medicine in Breast Cancer.

Authors:  Maria M Haykal; Sylvie Rodrigues-Ferreira; Clara Nahmias
Journal:  Cells       Date:  2021-05-01       Impact factor: 6.600

9.  Effect of angiotensin II type 2 receptor-interacting protein on adipose tissue function via modulation of macrophage polarization.

Authors:  Fei Jing; Masaki Mogi; Li-Juan Min; Kousei Ohshima; Hirotomo Nakaoka; Kana Tsukuda; Xiaoli Wang; Jun Iwanami; Masatsugu Horiuchi
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

10.  How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations?

Authors:  Marie-Odile Guimond; Nicole Gallo-Payet
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-19       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.